

Contents

List of Contributors *xix*

Preface *xxv*

About the Editors *xxvii*

Part I Current Antibiotics and Their Mechanism of Action 1

1 Resistance to Aminoglycosides: Glycomics and the Link to the Human Gut Microbiome 3

Viviana G. Correia, Benedita A. Pinheiro, Ana Luísa Carvalho, and Angelina S. Palma

1.1 Aminoglycosides as Antimicrobial Drugs 3

1.1.1 The Structure of Aminoglycosides 5

1.1.2 Mechanisms of Action 8

1.2 Mechanisms of Resistance 10

1.2.1 Aminoglycoside-Modifying Enzymes 10

1.2.2 Mutation or Modification of Ribosomal Target Sequences 13

1.2.3 Changes in Uptake and Efflux 14

1.3 Development of New AGAs: The Potential of Glycomics 16

1.3.1 Exploitation of Carbohydrate Chemistry to Study Structure–Activity Relationship of Aminoglycoside Derivatives 17

1.3.2 Aminoglycoside Microarrays to Screen Interactions of Antibiotics with RNAs and Proteins 18

1.4 Influence of the Human Microbiome in Aminoglycoside Resistance 20

1.4.1 The Effect of Antibiotic-Induced Alterations 21

1.4.1.1 Immunological Diseases: Compromised Host Homeostasis and Tolerance 22

1.4.1.2 Metabolic Diseases: Deregulated Metabolism 23

1.4.1.3 Infectious Diseases: Increased Susceptibility to Pathogens 23

1.4.2 A Reservoir of Antibiotic Resistance 24

1.4.3	Strategies to Modulate the Human Microbiome	25
1.5	Conclusions and Outlook	26
	Acknowledgments	27
	References	28
2	Mechanisms of Action and of Resistance to Quinolones	39
	<i>José L. Martínez</i>	
2.1	Introduction	39
2.2	Mechanism of Action of Quinolones	40
2.3	Mutations in the Genes Encoding the Targets of Quinolones	41
2.4	Multidrug Efflux Pumps and Quinolone Resistance	42
2.5	Transferable Quinolone Resistance	43
2.6	<i>Stenotrophomonas maltophilia</i> and Its Uncommon Mechanisms of Resistance to Quinolones	46
	Acknowledgments	47
	References	47
3	Beta-Lactams	57
	<i>Luz Balsalobre, Ana Blanco, and Teresa Alarcón</i>	
3.1	Introduction	57
3.2	Chemical Structure	58
3.3	Classification and Spectrum of Activity	59
3.3.1	Penicillins	59
3.3.1.1	Natural Penicillins	59
3.3.1.2	Semisynthetic Penicillins	60
3.3.2	Cephalosporins	61
3.3.2.1	First Generation	61
3.3.2.2	Second Generation	62
3.3.2.3	Third Generation	62
3.3.2.4	Fourth Generation	62
3.3.2.5	Fifth Generation	63
3.3.3	Monobactams	63
3.3.4	Carbapenems	64
3.3.5	Beta-Lactam Associated with Beta-Lactamase Inhibitors	64
3.4	Mechanism of Action	66
3.5	Activity of Beta-Lactams Against Multiresistant Bacteria	68
3.6	Conclusions	70
	References	70
4	Glycopeptide Antibiotics: Mechanism of Action and Recent Developments	73
	<i>Paramita Sarkar and Jayanta Haldar</i>	
4.1	Introduction	73
4.2	Naturally Occurring Glycopeptide Antibiotics	75

4.3	Mechanism of Action of Glycopeptide Antibiotics	76
4.4	Resistance to Glycopeptides	78
4.5	Second-Generation Glycopeptides	79
4.5.1	Telavancin	79
4.5.2	Dalbavancin	80
4.5.3	Oritavancin	80
4.6	Strategies to Overcome Resistance to Glycopeptides	81
4.6.1	Modifications That Enhance the Binding Affinity to Target Pentapeptide	81
4.6.1.1	Peptide Backbone Modification	81
4.6.1.2	Attachment of H-Bond-Forming Moieties	82
4.6.1.3	Development of Homomeric Multivalent Analogues	83
4.6.2	Incorporation of Lipophilicity	85
4.6.3	Incorporation of Lipophilic Cationic Moieties to Impart Membrane Disruption Properties	86
4.6.4	Incorporation of Metal Chelating Moiety to Vancomycin to Impart New Mechanism of Action	88
4.7	Glycopeptides Under Clinical Trials	88
4.8	Glycopeptide Antibiotics: The Challenges	90
	References	91
5	Current Macrolide Antibiotics and Their Mechanisms of Action	97
	<i>S. Lohsen and D.S. Stephens</i>	
5.1	Introduction	97
5.2	Structure of Macrolides	99
5.3	Macrolide Mechanisms of Action	101
5.4	Clinical Use of Macrolides	104
5.5	Next-Generation Macrolides and Future Use	107
	References	109
	Part II Mechanism of Antibiotic Resistance	119
6	Impact of Key and Secondary Drug Resistance Mutations on Structure and Activity of β-Lactamases	121
	<i>Egorov Alexey, Ulyashova Mariya, and Rubtsova Maya</i>	
6.1	Introduction	121
6.2	Structure of the Protein Globule of TEM-Type β -Lactamases: Catalytic and Mutated Residues	122
6.2.1	Catalytic Site of β -Lactamase TEM-1	124
6.2.2	Mutations Causing Phenotypes of TEM-Type β -Lactamases	125
6.3	Effect of the Key Mutations on Activity of TEM-Type β -Lactamases	127

6.3.1	Single Key Mutations in TEM-Type ESBLs (2be)	128
6.3.2	Combinations of Key Mutations in TEM-Type ESBLs (2be)	130
6.3.3	Key Mutations in IRT TEM-Type β -Lactamases (2br)	131
6.3.4	Single Key Mutations in IRT TEM-Type β -Lactamases (2br)	131
6.3.5	Combinations of Key Mutations in IRT TEM-Type β -Lactamases (2br)	133
6.3.6	Combinations of Key ESBL and IRT Mutations in CMT TEM-Type β -Lactamases (2ber)	133
6.4	Effect of Secondary Mutations on the Stability of TEM-Type β -Lactamases	134
6.5	Conclusions	135
	Abbreviations	136
	References	137
7	Acquired Resistance from Gene Transfer	141
	<i>Elisabeth Grohmann, Verena Kohler, and Ankita Vaishampayan</i>	
7.1	Introduction	141
7.2	Horizontal Gene Transfer: A Brief Overview	143
7.2.1	Transformation	144
7.2.2	Transduction	144
7.2.3	Conjugation	145
7.3	Conjugative Transfer Mechanisms	145
7.3.1	Conjugative Transfer of Plasmids	146
7.3.2	Conjugative Transfer of Integrative Conjugative Elements	148
7.3.3	Conjugative Transfer of Other Integrative Elements	150
7.4	Antibiotic Resistances and Their Transfer	151
7.4.1	Dissemination of Carbapenem Resistance Among Bacterial Pathogens	151
7.4.2	Dissemination of Cephalosporin Resistance Among Bacterial Pathogens	153
7.4.3	Dissemination of Methicillin Resistance Among Bacterial Pathogens	153
7.4.4	Dissemination of Vancomycin Resistance Among Bacterial Pathogens	154
7.4.5	Dissemination of Fluoroquinolone Resistance Among Bacterial Pathogens	154
7.4.6	Dissemination of Penicillin and Ampicillin Resistance Among Bacterial Pathogens	155
7.5	Nanotubes Involved in Acquisition of Antibiotic Resistances	155
7.6	Conclusions and Outlook	156
	Abbreviations	156
	References	157

9.3.5	Electrical Methods	196
9.3.6	Photodynamic Therapy	196
9.4	Conclusion	197
	Acknowledgments	197
	Conflict of Interest	197
	References	197
 Part III Socio-Economical Perspectives and Impact of AR 211		
10	Sources of Antibiotic Resistance: Zoonotic, Human, Environment	213
	<i>Ivone Vaz-Moreira, Catarina Ferreira, Olga C. Nunes, and Célia M. Manaia</i>	
10.1	The Antibiotic Era	213
10.2	Intrinsic and Acquired Antibiotic Resistance	214
10.3	The Natural Antibiotic Resistome	215
10.4	The Contaminant Resistome	215
10.5	Evolution of Antibiotics Usage	216
10.6	Antibiotic Resistance Evolution	219
10.7	Stressors for Antibiotic Resistance	219
10.8	Paths of Antibiotic Resistance Dissemination	221
10.9	Antibiotic Resistance in Humans and Animals	224
10.10	Final Considerations	227
	References	228
 11	 Antibiotic Resistance: Immunity-Acquired Resistance: Evolution of Antimicrobial Resistance Among Extended-Spectrum β-Lactamases and Carbapenemases in <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i>	 239
	<i>Isabel Carvalho, Nuno Silva, João Carrola, Vanessa Silva, Carol Currie, Gilberto Igrejas, and Patrícia Poeta</i>	
11.1	Overview of Antibiotic Resistance as a Worldwide Health Problem	239
11.2	Objectives	241
11.3	Causes of Antimicrobial Resistance	242
11.4	<i>Enterobacteriaceae</i> : General Characterization	243
11.4.1	<i>Escherichia coli</i>	243
11.4.2	<i>Klebsiella pneumoniae</i>	244
11.5	Current Antibiotic Resistance Threats	245
11.5.1	Carbapenem-Resistant <i>Enterobacteriaceae</i>	245
11.5.2	Extended-Spectrum β -Lactamase	247
11.6	Consequences and Future Strategies to Brace the Antibiotic Backbone	250
11.7	Concluding Remarks and Future Perspectives	251
	Acknowledgments	252
	References	252

8	Antimicrobial Efflux Pumps	167
	<i>Manuel F. Varela</i>	
8.1	Bacterial Antimicrobial Efflux Pumps	167
8.1.1	Active Drug Efflux Systems	167
8.1.1.1	Primary Active Drug Transporters	167
8.1.1.2	Bacterial ABC Drug Transporters	168
8.1.2	Secondary Active Drug Transporters	169
8.1.2.1	Bacterial MFS Drug Efflux Pumps	169
8.1.2.2	Bacterial RND Multidrug Efflux Pumps	170
8.1.2.3	Bacterial MATE Drug Pumps	170
8.1.2.4	SMR Superfamily of Drug Efflux Pumps	171
8.1.2.5	PACE Family of Drug Transporters	172
	References	173
9	Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved	181
	<i>Anne Jolivet-Gougeon and Martine Bonnaure-Mallet</i>	
9.1	Introduction	181
9.2	Reasons for Failure of Antibiotics in Biofilms	182
9.2.1	Failure of Antibiotics to Penetrate Biofilm: Active Antibiotics on the Biofilm	182
9.2.2	Outer Membrane Vesicles (OMVs)	183
9.2.3	Horizontal Transfer of Encoding β -Lactamase Genes	184
9.2.4	Influence of Subinhibitory Concentrations of Antibiotics on Biofilm	184
9.2.5	Small Colony Variants (SCVs), Persistence (Persisters), and Toxin–Antitoxin (TA) Systems	186
9.2.5.1	Small Colony Variants (SCVs)	186
9.2.5.2	Persisters	187
9.2.5.3	Toxin–Antitoxin (TA) Modules	189
9.2.6	Quorum Sensing: Bacterial Metabolites	191
9.2.7	Extracellular DNA	191
9.2.8	Nutrient Limitation	192
9.2.9	SOS Inducers (Antibiotics and Others)	192
9.2.10	Hypermutator Phenotype	192
9.2.11	Multidrug Efflux Pumps	193
9.3	Usual and Innovative Means to Overcome Biofilm Resistance in Biofilms	193
9.3.1	Antibiotics (Bacteriocins) Natural and Synthetic Molecules: Phages	194
9.3.2	Efflux Pump Inhibitors	195
9.3.3	Anti-Persisters: Quorum-Sensing Inhibitors	195
9.3.4	Enzymes	196

12	Extended-Spectrum-β-Lactamase and Carbapenemase-Producing Enterobacteriaceae in Food-Producing Animals in Europe: An Impact on Public Health? 261
	<i>Nuno Silva, Isabel Carvalho, Carol Currie, Margarida Sousa, Gilberto Igrejas, and Patrícia Poeta</i>
12.1	Extended-Spectrum β -Lactamase 261
12.1.1	ESBL-Producing <i>Enterobacteriaceae</i> in Food Animals 262
12.1.1.1	Poultry 262
12.1.1.2	Pigs 264
12.1.1.3	Cattle 265
12.2	Carbapenemases 265
12.3	Concluding Remarks 267
	References 268
	Part IV Therapeutic Strategy for Overcoming AR 275
13	AR Mechanism-Based Drug Design 277
	<i>Mire Zloh</i>
13.1	Introduction 277
13.2	Drug Design Principles 279
13.3	Identification of Novel Targets and Novel Mechanisms of Action 282
13.4	Efflux Pump Inhibitors 286
13.5	Design of Inhibitors of Drug-Modifying Enzymes 294
13.6	Antimicrobial Peptides 297
13.7	Other Approaches to Overcome Bacterial Resistance 299
13.8	Conclusion 300
	References 300
14	Antibiotics from Natural Sources 311
	<i>David J. Newman</i>
14.1	Introduction 311
14.1.1	The Origin of Microbial Resistance Gene Products 311
14.2	Organization of the Following Sections 312
14.3	Peptidic Antibiotics (Both Cyclic and Acyclic) 312
14.3.1	Tyrocidines, Gramacidins, and Derivatives 312
14.3.2	Streptogramins and Derivatives: Cyclic Peptides 313
14.3.3	Arylomycins (Lipopeptide and Modification, Preclinical) 313
14.3.4	Daptomycin (Cyclic Depsilipeptide) 314
14.3.4.1	Analogues of Daptomycin 315
14.3.5	Colistins (Cyclic Peptides with a Lipid Tail) 315
14.3.6	Glycopeptides 317
14.3.6.1	Vancomycin and Chemical Relatives 317

14.3.6.2	Synthetic Modifications of Vancomycin	318
14.3.7	Host Defense Peptides	319
14.3.7.1	Magainins and Derivatives	319
14.3.7.2	Synthetic Variations Using the “Defensin Concept”	320
14.4	β -Lactams: Development, Activities, and Chemistry	321
14.4.1	Combinations with β -Lactamase Inhibitors	322
14.5	Aminoglycosides	323
14.5.1	Streptomycin	323
14.5.2	Plazomicin	323
14.6	Early Tetracyclines: Aureomycin and Terramycin	324
14.6.1	Semisynthetic Tetracyclines from 2005	324
14.7	Erythromycin Macrolides	326
14.7.1	Recent Semisynthetic Macrolides	326
14.8	Current Methods of “Discovering Novel Antibiotics”	328
14.8.1	Introduction	328
14.8.2	Initial Rate-Limiting Step (Irrespective of Methods)	328
14.8.3	Genomic Analyses of Whole Microbes	329
14.8.3.1	Current Processes	329
14.8.4	Isolated Genomics	329
14.8.5	New Sources (and Old Ones?) for Investigation	331
14.8.6	“Baiting” for Microbes	331
14.8.7	Use of Elicitors	333
14.9	Conclusions	333
14.9.1	Funding?	334
14.9.2	The “Take-Home Lesson”	334
	References	334
15	Bacteriophage Proteins as Antimicrobials to Combat Antibiotic Resistance	343
	<i>Hugo Oliveira, Luís D. R. Melo, and Sílvia B. Santos</i>	
15.1	Introduction	343
15.2	Polysaccharide Depolymerases	346
15.2.1	Depolymerase Structure	348
15.2.2	Depolymerase Classification	349
15.2.3	Depolymerase Activity Assessment	350
15.2.4	Depolymerases as Antimicrobials	351
15.2.5	Remarks on Depolymerases	355
15.3	Peptidoglycan-Degrading Enzymes	356
15.3.1	Virion-Associated Lysins (VALs)	358
15.3.1.1	VAL Structure	358
15.3.1.2	VALs as Antimicrobials	359
15.3.1.3	Remarks on VALs	364
15.3.2	Gram-Positive Targeting Endolysins	365
15.3.2.1	Gram-Positive Targeting Endolysin Structure	365

15.3.2.2	Gram-Positive Targeting Endolysins as Antimicrobials	366
15.3.2.3	Remarks on Gram-Positive Targeting Endolysins	374
15.3.3	Gram-Negative Targeting Endolysins	374
15.3.3.1	Gram-Negative Targeting Endolysin Structure	375
15.3.3.2	Gram-Negative Targeting Endolysins as Antimicrobials	375
15.3.3.3	Remarks on Gram-Negative Targeting Endolysins	387
15.4	Holins	388
15.4.1	Holin Structure	388
15.4.2	Holins as Antimicrobials	389
15.4.3	Remarks on Holins	390
15.5	Final Considerations	390
	References	392
16	Antibiotic Modification Addressing Resistance	407
	<i>Haotian Bai and Shu Wang</i>	
16.1	Chemical Synthesis of New Antibiotics	407
16.2	Antibiotic Modification with Targeted Groups	413
16.3	Antibiotic Modification with Photo-Switching Units	417
16.4	Antibiotic Modification by Supramolecular Chemistry	420
16.5	Antibiotic Modification by Complexed with Other Materials	423
16.6	Conclusion	425
	References	425
17	Sensitizing Agents to Restore Antibiotic Resistance	429
	<i>Anton Gadellii, Karl-Omar Hassan, and Anders P. Hakansson</i>	
17.1	Introduction	429
17.2	Sensitizing Strategies Directly Targeting Resistance Mechanisms	430
17.2.1	Inhibition of β -Lactamases	430
17.2.2	Drug Efflux Pump Inhibitors (EPIs)	433
17.3	Sensitizing Strategies Circumventing Resistance Mechanisms	435
17.3.1	Manipulating Bacterial Homeostasis	435
17.3.2	Cell Wall/Membrane Proteins	437
17.3.3	Biofilms and Quorum Sensing	438
17.3.4	Persister Cells	440
17.3.5	Targeting Nonessential Genes/Proteins	441
17.3.6	Bacteriophages	441
17.4	Using and Strengthening the Human Immune System Against Resistant Bacteria	441
17.4.1	Strengthening Host Immune System Function	441
17.4.2	Antimicrobial Peptides (AMPs)	443
17.5	Conclusion	443
	References	444

18	Repurposing Antibiotics to Treat Resistant Gram-Negative Pathogens	453
	<i>Frank Schweizer</i>	
18.1	Introduction	453
18.2	Anti-Virulence Strategy	454
18.3	Antibiotic Combination Strategy	454
18.4	Antibiotic–Antibiotic Combination Approach	455
18.5	Antibiotic–Adjuvant Combination Approach	456
18.6	β -Lactam and β -Lactamase Inhibitor Combination	456
18.7	Imipenem–Cilastatin/Relebactam Triple Combination	457
18.8	Aspergillomarasmine A	458
18.9	Intrinsic Resistance Challenges and Strategies to Overcome Them	458
18.10	Repurposing of Hydrophobic Antibiotics with High Molecular Weight by Enhancing Outer Membrane Permeability Using Polybasic Adjuvants	461
18.11	Repurposing of Hydrophobic Antibiotics with Large Molecular Weight and Other Antibacterials as Antipseudomonal Agents Using Polybasic Adjuvants	464
18.12	Repurposing of Antibiotics as Potent Agents Against MDR GNB	467
18.13	Outlook and Conclusions	468
	References	468
19	Nontraditional Medicines for Treatment of Antibiotic Resistance	477
	<i>Ana Paula Guedes Frazzon, Michele Bertoni Mann, and Jeverson Frazzon</i>	
19.1	Introduction	477
19.2	Antibodies	478
19.2.1	Raxibacumab Versus <i>Bacillus anthracis</i>	478
19.2.1.1	Treatment and Mechanism of Action	478
19.2.2	Bezlotoxumab Versus <i>Clostridium difficile</i>	479
19.2.2.1	Treatment and Mechanism of Action	479
19.2.3	Panobacumab Versus <i>Pseudomonas aeruginosa</i>	479
19.2.4	LC10 Versus <i>Staphylococcus aureus</i>	480
19.3	Immunomodulators	481
19.3.1	Antibodies plus Polymyxins	481
19.3.2	Antibodies plus Vitamin D	482
19.3.3	Antibodies plus Clavanin	482
19.3.4	Antibodies plus Reltecimod	483
19.4	Potentiators of Antibiotic Activity	483
19.4.1	Antibiotic–Antibiotic Combinations	484
19.4.1.1	Targets in Different Pathways	484

19.4.1.2	Different Targets in the Same Pathway	484
19.4.1.3	Same Target in Different Ways	484
19.4.2	Pairing of Antibiotic with Nonantibiotic	485
19.4.2.1	Affecting a Vital Physiological Bacterial Function	485
19.4.2.2	Inhibition of Antibiotic Resistance Elements	485
19.4.2.3	Enhancement of the Uptake of the Antibiotic Through the Bacterial Membrane	486
19.4.2.4	Inhibit Efflux Pumps	487
19.4.2.5	Changing the Physiology of Resistant Cells	487
19.5	Bacteriophages	488
19.5.1	Life Cycles of Bacteriophages	488
19.5.2	Bacteriophage Therapy	489
19.5.3	Phage Enzymes	490
19.5.4	Concerns About the Application of Phage to Treat Bacteria	491
19.6	Therapy with Essential Oils	491
19.7	Microbiota-Based Therapy	495
19.7.1	Microbiota Modulation	495
19.7.1.1	Probiotics	496
19.7.1.2	Prebiotics	496
19.7.2	Stool Microbiota Transplant	496
	Further Reading	497
20	Therapeutic Options for Treatment of Infections by Pathogenic Biofilms	503
	<i>Bruna de Oliveira Costa, Osmar Nascimento Silva, and Octávio Luiz Franco</i>	
20.1	Introduction	503
20.2	Antibiotic Therapy for the Treatment of Pathogenic Biofilms	504
20.2.1	Monotherapy	504
20.2.2	Antibiotic Combination Therapy	505
20.3	New Findings for the Treatment of Pathogenic Biofilms	507
20.3.1	AMPs Applied to Treatment Pathogenic Biofilms	507
20.3.1.1	Synthetic Anti-Biofilm Peptides	508
20.3.1.2	Mechanism of Action	508
20.3.2	Bacteriophage Therapy Anti-Biofilm	514
20.3.3	Nanotechnology Applied to the Treatment of Pathogenic Biofilms	517
20.4	Conclusion and Future Directions	519
	References	520

Part V Strategies to Prevent the Spread of AR 533**21 Rapid Analytical Methods to Identify Antibiotic-Resistant Bacteria 535***John B. Sutherland, Fatemeh Rafii, Jackson O. Lay, Jr., and Anna J. Williams*

- 21.1 Introduction 535
- 21.2 Standard Methods for Antibiotic Sensitivity Testing 536
- 21.3 Rapid Cultural Methods 537
- 21.4 Rapid Serological Methods 540
- 21.5 Rapid Molecular (Genetic) Methods 540
- 21.6 Mass Spectrometric Methods 545
- 21.7 Flow Cytometric Methods 549
- 21.8 Conclusions 550
- Acknowledgments 553
- References 553

22 Effective Methods for Disinfection and Sterilization 567*Lucía Fernández, Diana Gutiérrez, Beatriz Martínez, Ana Rodríguez, and Pilar García*

- 22.1 Introduction 567
- 22.2 Disinfection and Sterilization: Methods and Factors Involved in Their Efficacy 569
 - 22.2.1 Methods of Sterilization and Disinfection 570
 - 22.2.2 Factors Influencing Disinfection and Sterilization Efficacy 570
- 22.3 Resistance to Disinfectants 571
 - 22.3.1 Molecular Mechanisms of Biocide Resistance 571
 - 22.3.2 Biofilms 572
 - 22.3.3 Cross-Resistance Between Antibiotics and Disinfectants 574
- 22.4 New Technologies as Alternatives to Classical Disinfectants 575
 - 22.4.1 Chemical and Physical Disinfectants 575
 - 22.4.1.1 Hydrogen Peroxide and Hydrogen Peroxide-Based Solutions 575
 - 22.4.1.2 Electrolyzed Water 576
 - 22.4.1.3 Cold-Air Atmospheric Pressure Plasma 577
 - 22.4.1.4 Steam Cleaning 577
 - 22.4.1.5 Ozone 577
 - 22.4.1.6 Ultraviolet Light Irradiation (UV-C) 577
 - 22.4.1.7 High-Intensity Narrow-Spectrum (HINS) Light 577
 - 22.4.1.8 Photocatalytic Disinfection 577
 - 22.4.2 Antimicrobial Surfaces 578
 - 22.4.3 Biological Disinfectants 578
 - 22.4.3.1 Bacteriophages or Phages 578
 - 22.4.3.2 Enzymes 579
 - 22.4.3.3 Bacteriocins 579

22.5	Current Legislation	579
22.6	Conclusions	581
	References	582
23	Strategies to Prevent the Spread of Antibiotic Resistance: Understanding the Role of Antibiotics in Nature and Their Rational Use	589
	<i>Rustam Aminov</i>	
23.1	Introduction	589
23.2	Agriculture as the Largest Consumer of Antimicrobials	590
23.3	Antimicrobials and Antimicrobial Resistance	591
23.4	First-Generation Tetracyclines: Discovery and Usage	592
23.5	Tetracycline Resistance Mechanisms	593
23.6	Phylogeny of Tetracycline Resistance Genes	593
23.7	Second-Generation Tetracyclines	595
23.8	Third-Generation Tetracyclines	595
23.9	Resistance to Third-Generation Tetracyclines	596
23.10	Other Potential Resistance Mechanisms Toward Third-Generation Tetracyclines	597
23.11	Evolutionary Aspect of <i>tet(X)</i>	598
23.12	Ecological Aspects of <i>tet(X)</i>	599
23.13	Antibiotics and Antibiotic Resistance as Integral Parts of Microbial Diversity	602
23.14	The Role of Antibiotics in Natural Ecosystems	604
23.15	Low-Dose Antibiotics: Phenotypic Effects	605
23.16	Low-Dose Antibiotics: Genetic Effects	606
23.17	Regulation of Antibiotic Synthesis in Antibiotic Producers	608
23.18	Convergent Evolution of Antibiotics as Signaling Molecules	610
23.19	Carbapenems: Convergent Evolution and Regulation in Different Bacteria	611
23.20	Antibiotics and Antibiotic Resistance: Environmental and Anthropogenic Contexts	614
23.21	Conclusions	615
	Conflict of Interest	616
	References	616
	Part VI Public Policy	637
24	Strategies to Reduce or Eliminate Resistant Pathogens in the Environment	639
	<i>Johan Bengtsson-Palme and Stefanie Heß</i>	
24.1	Introduction	639
24.2	Sources of Resistant Bacteria in the Environment	640

24.3	Sewage and Wastewater	641
24.3.1	Sewage Treatment Plants	641
24.3.2	Non-Treated Sewage	643
24.3.3	Industrial Wastewater Effluents	643
24.3.4	Environmental Antibiotic Resistance is a Poverty Problem	644
24.4	Agriculture	646
24.4.1	Intensive, Large-Scale Animal Husbandry	646
24.4.2	Manure Application	647
24.4.3	Agriculture in Developing Countries	647
24.4.4	Aquaculture	648
24.5	<i>De Novo</i> Resistance Selection	649
24.6	Relevant Risk Scenarios	649
24.7	Management Options	653
24.7.1	Possible Interventions on the Level of Releases of Resistant Bacteria	653
24.7.2	Restricting Transmission of Resistant Bacteria from the Environment	657
24.7.3	Better Agriculture Practices to Sustain the Lifespans of Antibiotics	658
24.7.4	Limiting Selection for Resistance in the Environment	659
24.8	Final Remarks	661
	Acknowledgments	662
	Conflict of Interest	662
	References	662
	Index	675